Mutational Profiling of SARS-CoV-2 PLpro in human cells reveals requirements for function, structure, and drug escape
Authors:
- Xinyu WuXWXinyu Wu
- Margareta GoMGMargareta Go
- Julie V. NguyenJNJulie V. Nguyen
- Bernadine G.C. LuBLBernadine G.C. Lu
- Kym N. LowesKLKym N. Lowes
- Dale J. CallejaDCDale J. Calleja
- Jeffrey P. MitchellJMJeffrey P. Mitchell
- Guillaume LesseneGLGuillaume Lessene
- David KomanderDKDavid Komander
- Melissa J. CallMCMelissa J. Call
Preprint
Abstract
SARS-CoV-2, the causative agent of COVID-19, is responsible for the recent global pandemic and remains a major source of mortality. Papain-like protease (PLpro) is a target for SARS-CoV-2 inhibitor development, as it is not only essential for viral replication through cleavage of the viral poly-proteins pp1a and pp1ab, but also has de-ubiquitylation and de-ISGylation activities, which can affect innate immune responses. To understand the features of PLpro that dictate activity and anticipate how emerging PLpro variants will affect function, we employed Deep Mutational Scanning to evaluate the mutational effects on enzymatic activity and protein stability in mammalian cells. We confirm features of the active site and identify all mutations in neighboring residues that support or ablate activity. We characterize residues responsible for substrate binding and demonstrate that although the blocking loop is remarkably tolerant to nearly all mutations, its flexibility is important for enzymatic function. We additionally find a connected network of mutations affecting function but not structure that extends far from the active site. Using our DMS libraries we were able to identify drug-escape variants to a common PLpro inhibitor scaffold and predict that plasticity in both the S4 pocket and blocking loop sequence should be considered during the drug design process.Keywords
All Related Versions
- Published version: Nature Communications, 15 (1), 1.
This publication has 73 references indexed in Scilit:
- A Patent Review on SARS Coronavirus Papain‐Like Protease (PLpro) InhibitorsChemMedChem, 2023
- High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitorsProtein & Cell, 2021
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020
- The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compoundsAntiviral Research, 2015
- Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site featuresAntiviral Research, 2014
- The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch MechanismImmunity, 2013
- Emerging Role of ISG15 in Antiviral ImmunityCell, 2010
- Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like proteaseArchives of Biochemistry and Biophysics, 2007
- Practical Methods of Optimization2000
- Structure of papain refined at 1.65 Å resolutionJournal of Molecular Biology, 1984